SLC5A2 and infection: Clinical implications of SGLT2-associated urogenital infections are focused on three main aspects: the initiation of this class of drugs in the presence of risk factors for urogenital infections, the necessity of discontinuation of the treatment if such an infection develops while taking SGLT2 inhibitors, and the reinitiation of drugs after a urogenital infection.